Prosecution Insights
Last updated: November 13, 2026
Application No. 18/288,850

Microneedle Based Delivery System

Final Rejection §102§103§112
Filed
Oct 30, 2023
Priority
May 10, 2021 — EU 21173092.4 +1 more
Examiner
WILLIAMS, CATHERINE SERKE
Art Unit
3993
Tech Center
3900
Assignee
Latch Medical Limited
OA Round
2 (Final)
62%
Grant Probability
Moderate
3-4
OA Rounds
92%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
80 granted / 128 resolved
+2.5% vs TC avg
Strong +30% interview lift
Without
With
+29.7%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
21 currently pending
Career history
154
Total Applications
across all art units

Office Action

§102 §103 §112
FINAL REJECTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1-18 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The new claim limitation of “the at least one first microneedle and the at least one second microneedle overlap in the direction of displacement relative to one another in … the disengaged state” is not disclosed in the specification or drawings. Response to Arguments In Applicant’s remarks filed 09/03/2026 attention is drawn to Figs. 1, 2, 4, 8c and 10 as showing the overlap of the first and second microneedles in the “X” direction. However, these figures do not show this orientation. Fig. 1 is disclosed as showing the microneedle based delivery system in the disengaged state. However, the microneedles themselves are barely visible and one skilled in the art would not be able to determine if the first and second microneedles are overlapping in the “X” direction. Fig. 2 is a closer view of the delivery system of Fig. 1. However, the first and second needles are not clearly overlapping in a “X” direction; rather, the needles seem to be laterally displaced with no overlapping. Fig. 4 shows a cut away perspective of the delivery system. Similar to Fig. 2, the first and second needles are not clearly overlapping in a “X” direction; rather, the needles seem to be laterally displaced with no overlapping. Fig. 8c shows a cross section of the delivery system in the disengaged state. However, the first and second needles are not clearly overlapping in a “X” direction; rather, the needles seem to be laterally displaced with no overlapping. Fig. 10 shows a front elevation of the delivery system of Fig. 9. Fig. 9 clearly shows that the first and second microneedles are not overlapping. The elevation of Fig. 10 does not clearly show that the first and second microneedles are overlapping in the “X” direction. Furthermore, the specification (para. [0073] in US Pub. No. 2024/0207589) states, “[r]eferring to FIG. 4 it can be seen that when the system 10 is in the disengaged state the upper ends of the delivery conduits 26, 28 are spaced from one another in the “X” direction” (emphasis added); therefore, the first and second microneedles are not overlapping in the disengaged state in the “X” direction. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. The previous rejection of claims 7-9 and 11-13 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, has been withdrawn in light of the amendment to the claims filed 09/03/2026. Claim Rejections - 35 USC § 102 The previous rejection of claim(s) 1-7, 10-11 and 16-18 under 35 U.S.C. 102(a)(1) as being anticipated by WO2012/006677 to Kendall et al. (“Kendall”) has been withdrawn in light of the amendment to the claims filed 09/03/2026. Kendall does not disclose or render obvious the at least one first microneedle and the at least one second microneedle overlap in the direction of displacement relative to one another in both the disengaged state and the engaged state. The previous rejection of claim(s) 1 and 6-10 under 35 U.S.C. 102(a)(1) as being anticipated by US2009/0270906 to Hossainy (“Hossainy”) has been withdrawn in light of the amendment to the claims filed 09/03/2026. Hossainy does not disclose or render obvious the at least one first microneedle and the at least one second microneedle overlap in the direction of displacement relative to one another in both the disengaged state and the engaged state. Claim Rejections - 35 USC § 103 The previous rejection of claim(s) 14-15 under 35 U.S.C. 103 as being unpatentable over Kendall in view of US2019/0134370 to Sumida (“Sumida”) has been withdrawn in light of the amendment to the claims filed 09/03/2026. See above. Response to Arguments Applicant’s arguments, filed 09/03/2026, with respect to the claim amendment to claim 1 have been fully considered and are persuasive. The previous rejections been withdrawn. Pertinent Prior Art The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. WO2013/090844; KR20070091115 and WO03/074102. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERINE SERKE WILLIAMS whose telephone number is (571)272-4970. The examiner can normally be reached Monday through Friday core hours 8am-4pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Eileen Lillis can be reached at 571-272-6928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CATHERINE S WILLIAMS/Primary Examiner, Art Unit 3993
Read full office action

Prosecution Timeline

Oct 30, 2023
Application Filed
Mar 04, 2026
Non-Final Rejection mailed — §102, §103, §112
Sep 03, 2026
Response Filed
Oct 21, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent RE51102
TOOTH PREPARATION GUIDE DEVICE AND METHOD OF PREPARING TOOTH FOR DENTAL PROSTHESIS
3y 6m to grant Granted Nov 03, 2026
Patent 12741120
CATHETER
3y 8m to grant Granted Sep 22, 2026
Patent RE50991
METHOD AND APPARATUS FOR TREATMENT OF RESPIRATORY DISORDERS
5y 0m to grant Granted Aug 18, 2026
Patent RE50949
TEXTURED WOVEN FABRIC FOR USE IN IMPLANTABLE BIOPROSTHESES
3y 1m to grant Granted Jul 14, 2026
Patent RE50944
MONITORING UNIT
3y 3m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
62%
Grant Probability
92%
With Interview (+29.7%)
Moderate
PTA Risk
Based on 128 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month